Structure Therapeutics
NASDAQ · GPCR·South San Francisco, CA·Mid-cap·Phase 3
Clinical-stage biopharma developing oral small-molecule GLP-1R agonists and metabolic therapeutics. Lead asset aleniglipron (GSBR-1290) is an oral GLP-1R agonist advancing into Phase 3 for obesity and Type 2 diabetes; pipeline includes ACCG-2671 and ACCG-3535.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Structure Therapeutics Corporate Presentation January 2026 | JPM Healthcare | January 13, 2026 | 44 |